Ipsogen Launches A New Test To Guide Hormonotherapy Prescription In Breast Cancer
Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announces the European launch of the MapQuant Dx(TM) HR test.
More: continued here
Filed under: Breast Cancer on May 9th, 2009
You must be logged in to post a comment.